| abstract |
[Chemical 1] Antagonist of prostaglandin E2 receptor subtype EP4 and treatment of medical conditions related to urinary nephropathy, bone resorption, abnormal intestinal crypt cell proliferation or patent ductus arteriosus, etc. These uses for prevention are provided herein. The antagonist peptide of the present invention has the general formula (I), wherein X is selected from the group consisting of a hydrogen atom, a series of 1 to 3 amino acids, and protecting groups such as carbamate and acyl groups, and Y is selected from the group consisting of a hydrogen atom, 1 to 5 lysine residues, phosphate, sulfate, and 1 to 5 ethylene glycol residues. |